Is Mankind Pharma a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Mankind Pharma Ltd is a good quality company .

Is Mankind Pharma undervalued or overvalued?

The key valuation ratios of Mankind Pharma Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone .

What is Mankind Pharma share price return in the past 10 years?

Data is not available for this company

Is Mankind Pharma a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Mankind Pharma Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

Mankind Pharma Ltd - Stock Valuation and Financial Performance

Name: Mankind Pharma
Brand: Mankind Pharma

BSE: 543904 | NSE: MANKIND | Pharmaceuticals & Drugs | Mid Cap

Place order

Mankind Pharma Share Price

₹2,803.45 -86.00 -2.98%
as on 20-Dec'24 16:59

10 Year X-Ray of Mankind Pharma:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis ^P

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
ROCE % ⓘ	31.8%	33.7%	32.7%	31.8%	22.1%	37%	34.2%	31.8%	21.2%	26.1%	-
Value Creation Index ⓘ	1.8	2.0	1.9	1.8	1.0	2.3	2.0	1.8	0.5	1.3	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	2,682	3,150	3,495	3,918	3,829	4,794	5,523	7,486	8,127	9,265	9,444
Sales YoY Gr.	-	17.4%	11%	12.1%	-2.3%	25.2%	15.2%	35.5%	8.6%	14%	-
Adj EPS ⓘ	9.4	11	12.2	16.3	12.3	23.5	26.9	34.4	30.9	45.4	49.2
YoY Gr.	-	16.5%	11.2%	33.4%	-24.3%	90.3%	14.8%	27.9%	-10.3%	46.9%	-
BVPS (₹) ⓘ	48.9	52.5	65.9	74.8	76.5	91.2	118.2	163.3	194.3	239.7	269.3
Adj Net Profit ⓘ	377	439	489	652	494	940	1,078	1,379	1,237	1,817	2,028
Cash Flow from Ops. ⓘ	326	482	507	540	537	960	983	821	1,799	1,983	-
Debt/CF from Ops. ⓘ	0	0	0	0.7	0.4	0	0.1	0.8	0	0	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	14.8%	19.3%	18.8%	14%
Adj EPS ⓘ	19.1%	29.8%	19%	46.9%
BVPSⓘ	19.3%	25.7%	26.6%	23.3%
Share Price	-	-	-	46.8%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
Return on Equity % ⓘ	21.5	21.6	20.6	23.1	16.3	28	25.7	24.5	17.3	20.9	19.3
Op. Profit Mgn % ⓘ	19.5	20.5	20.2	19.9	18.4	26	24.9	24.6	20.9	25.1	26.2
Net Profit Mgn % ⓘ	14.1	14	14	16.6	12.9	19.6	19.5	18.4	15.2	19.6	21.5
Debt to Equity ⓘ	0	0	0	0.1	0.1	0	0	0.1	0	0	0
Working Cap Days ⓘ	143	132	131	118	107	92	104	112	117	97	121
Cash Conv. Cycle ⓘ	28	17	15	9	5	7	19	17	12	16	85

Recent Performance Summary

Sales growth is growing at healthy rate in last 3 years 18.82%

Net Profit is growing at healthy rate in last 3 years 19.00%

Sales growth is good in last 4 quarters at 15.89%

Return on Equity has declined versus last 3 years average to 19.30%

Latest Financials - Mankind Pharma Ltd.

	Standalone	Consolidated
TTM EPS (₹)	49.2	51.3
TTM Sales (₹ Cr.)	9,444	11,018
BVPS (₹.) ⓘ	269.3	263.7
Reserves (₹ Cr.) ⓘ	13,652	10,526
P/BV ⓘ	10.41	10.63
PE ⓘ	57.03	54.69

From the Market
52 Week Low / High (₹)	1849.95 / 2920.05
All Time Low / High (₹)	1240.75 / 2920.05
Market Cap (₹ Cr.)	1,15,661
Equity (₹ Cr.)	41.3
Face Value (₹)	1
Industry PE ⓘ	44.3

Management X-Ray of Mankind Pharma:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Mankind Pharma

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Mankind Pharma

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Sales	2,682	3,150	3,495	3,918	3,829	4,794	5,523	7,486	8,127	9,265
Operating Expenses ⓘ	2,161	2,504	2,793	3,139	3,124	3,550	4,151	5,648	6,429	6,939
Manufacturing Costs	32	53	74	103	106	147	178	198	192	230
Material Costs	1,085	1,199	1,296	1,431	1,392	1,573	1,782	2,521	2,845	2,908
Employee Cost	432	573	663	798	785	991	1,167	1,463	1,701	1,982
Other Costs ⓘ	612	679	761	808	841	839	1,023	1,466	1,691	1,819
Operating Profit ⓘ	522	645	701	779	705	1,244	1,372	1,838	1,698	2,326
Operating Profit Margin (%)	19.5%	20.5%	20.1%	19.9%	18.4%	25.9%	24.8%	24.6%	20.9%	25.1%
Other Income ⓘ	73	76	89	201	64	94	155	204	163	267
Interest ⓘ	1	2	2	19	40	11	8	48	28	15
Depreciation ⓘ	36	38	16	28	38	62	78	123	270	318
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	0	0
Profit Before Tax ⓘ	558	681	772	933	691	1,265	1,440	1,871	1,563	2,260
Tax ⓘ	155	207	240	247	177	307	356	482	315	436
Profit After Tax	404	475	532	686	514	958	1,084	1,389	1,248	1,823
PAT Margin (%)	15.0%	15.1%	15.2%	17.5%	13.4%	20.0%	19.6%	18.6%	15.4%	19.7%
Adjusted EPS (₹)	10.1	11.9	13.3	17.1	12.8	23.9	27.1	34.7	31.2	45.5
Dividend Payout Ratio (%)	0%	63%	0%	25%	35%	13%	0%	0%	0%	0%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Equity and Liabilities
Shareholders Fund	1,959	2,102	2,639	2,997	3,065	3,651	4,734	6,540	7,784	9,601
Share Capital ⓘ	20	20	20	40	40	40	40	40	40	40
Reserves ⓘ	1,939	2,082	2,619	2,957	3,025	3,611	4,694	6,500	7,744	9,561
Minority Interest	0	0	0	0	0	0	0	0	0	0
Debt	0	0	0	360	190	0	95	684	0	0
Long Term Debt	0	0	0	0	0	0	0	0	0	0
Short Term Debt	0	0	0	360	190	0	95	684	0	0
Trade Payables	284	326	368	452	387	487	594	921	802	850
Others Liabilities ⓘ	67	99	165	200	209	371	444	793	785	968
Total Liabilities ⓘ	2,309	2,528	3,172	4,009	3,851	4,510	5,867	8,939	9,371	11,418
Fixed Assets
Gross Block	341	279	533	601	883	1,111	1,222	3,287	3,770	4,337
Accumulated Depreciation	119	36	51	78	116	172	240	366	633	938
Net Fixed Assetsⓘ	222	243	481	523	768	939	982	2,921	3,137	3,399
CWIP ⓘ	45	70	141	322	211	148	166	387	495	188
Investmentsⓘ	944	768	986	1,402	1,698	1,784	2,397	2,526	3,102	4,430
Inventories	399	410	522	469	482	533	827	1,267	1,032	1,076
Trade Receivables	169	157	137	243	139	419	369	471	493	749
Cash Equivalents	41	69	92	81	72	198	477	139	155	761
Others Assetsⓘ	490	810	812	970	481	489	650	1,229	957	815
Total Assets ⓘ	2,309	2,528	3,172	4,009	3,851	4,510	5,867	8,939	9,371	11,418

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Cash Flow From Operating Activity ⓘ	326	482	507	540	537	960	983	821	1,799	1,983
PBT ⓘ	558	681	772	933	691	1,265	1,440	1,871	1,563	2,260
Adjustment ⓘ	5	-6	-8	-70	32	137	97	-4	227	162
Changes in Working Capital ⓘ	-45	13	-29	-73	59	-168	-156	-586	294	-41
Tax Paid ⓘ	-153	-206	-226	-250	-246	-274	-397	-460	-285	-398
Cash Flow From Investing Activity ⓘ	-382	-103	-513	-516	-306	-396	-1,127	-1,360	-1,041	-1,919
Capex	-287	-64	-280	-231	-165	-164	-192	-2,181	-580	-250
Net Investments	0	108	-32	185	88	-165	-958	680	-506	-1,743
Others ⓘ	-95	-146	-202	-471	-229	-67	23	141	45	75
Cash Flow From Financing Activityⓘ	-1	-363	-1	8	-240	-559	89	579	-710	-9
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	0	0	0	0	0	0	0	0	0	0
Interest Paid ⓘ	-1	-1	-1	-16	-41	-4	-5	-7	-26	-7
Dividend Paid ⓘ	0	-300	0	-300	-24	-302	0	0	0	0
Others ⓘ	0	-61	0	324	-175	-253	94	586	-684	-2
Net Cash Flow ⓘ	-57	17	-8	31	-9	5	-55	40	48	55

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Ratios
ROE (%)	22.97	23.38	22.43	24.35	16.96	28.53	25.86	24.65	17.43	20.98
ROCE (%)	31.84	33.65	32.65	31.75	22.11	36.95	34.16	31.84	21.2	26.13
Asset Turnover Ratio	1.2	1.31	1.23	1.09	1.01	1.19	1.1	1.05	0.93	0.93
PAT to CFO Conversion(x)	0.81	1.01	0.95	0.79	1.04	1	0.91	0.59	1.44	1.09
Working Capital Days
Receivable Days	20	19	15	18	18	20	25	20	21	24
Inventory Days	50	47	48	46	44	37	43	49	50	40
Payable Days	77	93	98	105	110	101	111	110	111	104

Mankind Pharma Ltd Stock News

Mankind Pharma Ltd FAQs

What is the share price of Mankind Pharma?

Company share prices are keep on changing according to the market conditions. The closing price of Mankind Pharma on 20-Dec-2024 16:59 is ₹2,803.5.

What is the market cap of Mankind Pharma?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 20-Dec-2024 16:59 the market cap of Mankind Pharma stood at ₹1,15,661.1.

What is the P/E ratio of Mankind Pharma?

The latest P/E ratio of Mankind Pharma as of 20-Dec-2024 16:59 is 57.03.

What is the P/B ratio of Mankind Pharma?

The latest P/B ratio of Mankind Pharma as of 20-Dec-2024 16:59 is 10.41.

What is the 52-week high and low of Mankind Pharma?

The 52-week high of Mankind Pharma is ₹2,920.1 and the 52-week low is ₹1,850.

What is the TTM revenue of Mankind Pharma?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Mankind Pharma is ₹9,444 ( Cr.) .

About Mankind Pharma Ltd

Mankind Pharma was incorporated on July 3, 1991 as a private limited company under the Companies Act, 1956, with the name ‘Mankind Pharma Private Limited’, pursuant to a certificate of incorporation granted by the Registrar of Companies, Delhi and Haryana, at New Delhi (RoC). Pursuant to the conversion of the company to a public limited company and as approved by its shareholders pursuant to a special resolution dated July 14, 2005 the name of the company was changed to ‘Mankind Pharma Limited’ and the RoC issued a fresh certificate of incorporation on April 13, 2006.

The company is India’s fourth largest pharmaceutical company in terms of domestic sales and third largest in terms of sales volume for MAT December 2022 (Source: IQVIA Dataset, IQVIA TSA MAT December 2022 Dataset for India (For FY20-22)).It is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. It has primarily grown organically and are the youngest company among the five largest pharmaceutical companies in India, in terms of Domestic Sales in 2022 (Source: IQVIA Dataset, Annual filings / company data). It operates at the intersection of the Indian pharmaceutical formulations and consumer healthcare sectors with the aim of providing quality products at affordable prices, and has an established track record of building and scaling brands in-house. It has created many brands in its pharmaceutical business.

It is present in several acute and chronic therapeutic areas in India, including anti- infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, vitamins /minerals /nutrients and respiratory. It entered the consumer healthcare industry in 2007 and has since established several differentiated brands in the condoms, pregnancy detection, emergency contraceptives, antacid powders, vitamin and mineral supplements and anti-acne preparations categories.

Business area of the company

The company is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products.

Therapeutic Area

Anti-infectives
Cardiovascular
Gastrointestinal
Vitamins/minerals/nutrients
Respiratory
Anti-diabetic
Dermatology
Gynaecology
Pain/analgesics
Neuro/CNS

Brands of the company

Nurokind
Telmikind
Manforce
Unwanted
Moxikind
Gudcef
Glimestar
Amlokind
Asthakind
Dydroboon
Prega News
Candiforce
Codistar
Mahacef
Cefakind
Zenflox
Monticope
Vomikind
Caldikind
Dynaglipt

Awards, accreditations or recognition

2007: Emerging Company of the year award at the Pharma Excellence Awards 2007.
2011: Amity HR Excellence Award for Performance Management at the 8th Global HR Summit 2011.
2017: Award for Best Design in Healthcare at Healthcare Leadership Awards 2017.
2018: Best Condom Brand of the Year award at Sex Brand Awards.
2018: Pharma OTC company of the year award at Pharma Excellence Awards 2018.
2021: Silver Medal from National Awards for Manufacturing Competitiveness Assessment 2021 instituted by International Research Institute for manufacturing.
2021: Silver Award for Good Health Brand at IHW Awards 2021.
2022: E4m Pride of India - The Best of Bharat Awards 2022 by exchange4media.
2022: Award for Branding and Marketing Excellence for the Strategic Initiative to Introduce DMF Quality Drugs in India at National Awards for Leadership & Excellence 2022.
2022: EHS Best Practices award at Greentech International EHS Award 2023.
2022: Docflix won the Digital Jalebi (DJ Interactive Solutions) award at the Maddies 2022.
2022: Best Energy Efficient Case Study (SME Category) at CII National Energy Efficiency Circle Competition by Confederation of Indian Industry.
2022: Short film, she can carry both by Prega News won 1st prize at Council for Fair Business Practices Consumer Film Festival.

History and milestones

2004: Entered the chronic pharmaceutical segment with the launch of ‘Amlokind’ tablets and ‘Glimestar’ tablets amongst others.
2005: Set up its first manufacturing facility at Paonta Sahib, Himachal Pradesh.
2005: Entered the ophthalmic pharmaceutical segment with the launch of ‘Lubistar Eye Drops’ and ‘Tobastar Eye Drops’ amongst others.
2007: Entered the consumer healthcare segment with the launch of ‘Manforce’ brand. 2007: Entered the animal healthcare segment with launch of ‘Bandykind’ and ‘Ceftiforce’ amongst others.
2007: Raised Rs 72 crore from Monet Limited.
2009: Set up its manufacturing facility at Unit II, Paonta Sahib, Himachal Pradesh.
2010: Launched ‘Preganews’ brand in the consumer healthcare segment.
2012: Setup its first R&D centre at IMT Manesar, Haryana.
2014: Acquired Shree Jee Laboratory Private Limited (along with its API manufacturing site situated at Behror, Rajasthan).
2014: Set up its manufacturing facility at Unit III, Paonta Sahib, Himachal Pradesh
2015: Incorporated its Subsidiary, Lifestar Pharma LLC in the US.
2015: Incorporated its Subsidiary, Mankind Pharma Pte. Limited in Singapore.
2017: Set up its manufacturing facility in Sikkim.
2018: Its manufacturing facility at Paonta Sahib, Himachal Pradesh was inspected by the USFDA for the first time.
2019: Entered the female infertility segment with the launch of ‘Dydroboon’ tablets.
2020: Incorporated its Subsidiary, Lifestar Pharmaceuticals Private Limited in Nepal.
2020: Launched a dedicated specialty therapeutic division for cardiovascular diseases drugs segment with launch of ‘Cilaheart’ tablets and ‘Statpure’ tablets.
2020: Launched a dedicated specialty therapeutic division for diabetes pharmaceuticals segment with launch of ‘Zukanorm’ tablets.
2021: Incorporated its Subsidiary, Mankind Pharma FZ-LLC in Dubai, UAE.
2021: Launched a specialty division for therapeutic respiratory pharmaceuticals with launch of ‘Mlife’ tablets.
2021: Entered the specialty therapeutic neuro/central nervous system pharmaceuticals segment with launch of ‘Trugaba-NT’ tablets and ‘Prebris-MNT’ tablets.
2022: Acquired the pharmaceutical formulations brands in India and Nepal from Panacea Biotec Pharma Limited and Panacea Biotec Limited.
2022: Entered into transplant segment with the launch of ‘Pangraf Capsules’ and ‘Mycept’ tablets amongst others.
2022: Entered into oncology segment with the launch of ‘Pacliall’ injection amongst others.
2022: Acquired the brands ‘Daffy’ and ‘Combihale’ from Dr. Reddy’s Laboratories.